AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Rhythm Pharmaceuticals, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG007DLZ629
89.27▼ 1.63 (-1.79%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
90.90
Day's Range
88.56 – 90.44
52-Week Range
73.75 – 122.20
Volume
527.2K
Avg Volume
717.1K
Share Statistics
Shares Outstanding
Employees
414
Exchange
XNAS
Listed
2017-10-05
Share count as of August 1, 2026

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)
What is Rhythm Pharmaceuticals, Inc. Common Stock's Market Cap?
Rhythm Pharmaceuticals, Inc. Common Stock's Market Cap is $6.1B, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Enterprise Value?
Rhythm Pharmaceuticals, Inc. Common Stock's Enterprise Value is $6.0B, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Price / Sales?
Rhythm Pharmaceuticals, Inc. Common Stock's Price / Sales is 25.6×, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's EV / Revenue?
Rhythm Pharmaceuticals, Inc. Common Stock's EV / Revenue is 25.2×, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's EV / EBITDA?
Rhythm Pharmaceuticals, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Revenue (TTM)?
Rhythm Pharmaceuticals, Inc. Common Stock's Revenue (TTM) is $239.9M, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
Rhythm Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$205.3M, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's EBITDA?
Rhythm Pharmaceuticals, Inc. Common Stock's EBITDA is -$200.1M, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
Rhythm Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -2.98, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's EBITDA Margin?
Rhythm Pharmaceuticals, Inc. Common Stock's EBITDA Margin is -83.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RYTMAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Total revenues
YoY growth+46.9%+83.8%+36.9%+54.3%
Costs and expenses:
Cost of sales
Research and development
Selling, general, and administrative
Total costs and expenses
% of revenue168.1%187.1%182.2%202.6%
Loss from operations
% of revenue-68.1%-87.1%-82.2%-102.6%
Other income (expense):
Other income (expense), net
Interest expense
Interest income
Total other expense, net
Loss before income taxes
Provision for income taxes
Net loss
% of revenue-69.2%-92.6%-83.0%-103.1%
Accrued dividends on convertible preferred stock
Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic (in dollars per share)
Net loss per share attributable to common stockholders, diluted (in dollars per share)